Article | June 12, 2025
In this GIR article, Stephen Millington and Dominique Dondelinger examine the growing fraud risks facing the Gulf region amid rapid economic expansion and transformative Vision 2030 strategies.
November 18, 2024
Richard Manning provided trial testimony that contributed to a decisive legal victory for biotech startup Inhibrx in a $460 million trade secrets case brought by I-Mab Biopharma in Delaware federal district court.
Secretariat was engaged by law firms Potter Anderson and Wilson Sonsini to provide expert testimony and respond to Plaintiff’s damages claims for this case on behalf of their clients, Inhibrx Biosciences and Inhibrix co-founder Dr. Brendan Eckelman.
On November 1, 2024, a federal jury in the US District Court for the District of Delaware unanimously sided with Inhibrx, rejecting all allegations of misappropriation and finding that the data in question did not qualify as legally-protectable trade secrets.
“I am pleased that my testimony was accepted by the court and helped the jury reach a verdict,” said Dr. Manning. “I trust that my economic analysis, combined with my prior experience in the biopharmaceutical industry, helped the jury understand the facts of this complex, high-stakes case.”
I-Mab filed the lawsuit on March 1, 2022, claiming that Inhibrx and Dr. Eckleman misappropriated confidential information related to I-Mab research projects during prior arbitration proceedings involving I-Mab, for which Dr. Eckelman had served as an expert witness. The Delaware jury found no basis for these claims and awarded the plaintiff $0 in damages, based in part on Dr. Manning’s testimony. The jury’s findings marked a complete victory for Inhibrx and Dr. Eckelman.
Read more about this case on Law360 (subscription required).
In this GIR article, Stephen Millington and Dominique Dondelinger examine the growing fraud risks facing the Gulf region amid rapid economic expansion and transformative Vision 2030 strategies.
Public Cos. Must Heed Disclosure Risks Amid Trade Chaos
Ongoing uncertainties caused by the trade war and President Donald Trump’s evolving stance on tariffs and trade restrictions, including sanctions and export controls, have exponentially escalated financial reporting pressures on public companies. In this article, we discuss the key financial reporting and disclosure risks, as well as takeaways, for public companies as they navigate significant market instability in international trade.
Tanner Weil and Marc Pichon will present their paper, “Leveraging Business Intelligence Platforms for Data Analytics in Forensic Schedule Analysis & Quantification of Damages for Construction Projects” at the Association for the Advancement of Cost Engineering (AACE) 2025 Conference & Expo, taking place June 15-17 in Anaheim, California.